General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Crohn's disease
Last updated December 19, 2025
Myfembree (relugolix, estradiol, and norethindrone acetate)
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Management of heavy menstrual bleeding associated with uterine fibroids
Last updated December 12, 2025
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Last updated December 11, 2025
Omnipod 5 (Automated Insulin Delivery System)
Status:
Concluded with an LOI
Manufacturer:
Insulet Canada Corporation
Indication:
Patients with Type 1 Diabetes aged 2 years and old
Last updated December 11, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated December 10, 2025
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Last updated December 3, 2025
Status:
Negotiations were not pursued (Manufacturer withdrew from negotiation)
Manufacturer:
Amgen Canada Inc.
Indication:
Advanced non-small cell lung cancer, KRAS G12C-mutated
Last updated December 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Last updated December 1, 2025
Status:
Concluded without agreement (Manufacturer declined negotiation)
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Last updated December 1, 2025
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.
Last updated November 28, 2025